Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...